Takeda's Edarbi Oked in EU
In another piece of positive news for Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502), the company said last week that the European Commission has granted marketing authorization for Edarbi (azilsartan medoxomil), a new once-daily angiotensin receptor blocker (ARB) - also known as angiotensin II receptor antagonist (AIIRA) - for the treatment of essential hypertension in adults.
Last week, along with partner Affymax, Takeda received US Food and Drug Administration clearance to market their peginesatide for use in the treatment of dialysis patients with anemia due to chronic kidney disease (CKD; The Pharma Letter December 9).
Takeda will launch azilsartan medoxomil across Europe in 2012 starting with Germany in January. The US FDA approved Edarbi to treat high blood pressure (hypertension) in adults early this year (TPL February 28) and the drug was launched in that market in April.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze